Enjaymo treats cold agglutinin disease, a condition in which the immune system attacks red blood cells and causes them to rupture. This process happens at cold temperatures, giving the disease its ...

Cold agglutinin disease is a rare clinical scenario. It is usually associated with infection, drug reaction, and hematologic malignancy, such as non-Hodgkin lymphoma or lymphocytic leukemia.

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

in patients with the uncommon blood disorder cold agglutinin disease (CAD). That same year, Sanofi’s C1 inhibitor also scored CAD green lights in Europe and Japan, Recordati noted in a press ...

Enjaymo, a humanized monoclonal antibody, is the only approved targeted product for cold agglutinin disease (CAD), a rare autoimmune disorder characterized by the premature destruction of red ...

Italian pharma group Recordati (RECI.MI), opens new tab said on Friday it would buy from Sanofi (SASY.PA), opens new tab the global rights to a drug used to treat cold agglutinin disease (CAD), a ...

Also known as cold agglutinin disease (CAD), this type of hemolytic anemia is rarer. Overall, the symptoms of warm and cold hemolytic anemia are similar and largely the same as those of anemia ...

Dogs have their own “common cold” called kennel cough, just like humans, which is a common occurrence throughout the year.

Sanofi has won FDA approval for its sutimlimab for cold agglutinin disease (CAD) at the second time of asking, becoming the first approved therapy for the rare blood disorder in the US.

In cold AIHA, also called cold agglutinin disease, antibodies are active at very cold temperatures (0º to 4°C or 32º to 39ºF). Alloimmune hemolytic anemia occurs when your body makes ...

Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment. UK to consider bill to ...